Jakura 5 mg (Tofacitinib) – 60 Tablets

Description

Product Features:

Indications and Uses of Jakura 5 mg

Therapeutic Indications

Jakura 5 mg is primarily prescribed for the following conditions:

Rheumatoid arthritis: A chronic inflammatory disorder that affects the joints.

Psoriatic Arthitis: Arthritis associated with psoriasis, a skin condition.

Ulcerative Colitis: A chronic inflammatory bowel disease that affects the lining of the colon.

Ankylosing Spondylitis: A kind of arthritis that mainly involves the spine.

In these conditions, Jakura 5 mg helps to reduce pain, swelling and stiffness in joints and improves physical function.

Pharmacology

Drug Classes

Jakura 5 mg is in a class of medications called Janus kinase (JAK) inhibitors. These two drugs act by inhibiting the activity of specific enzymes involved in inflammation.

Mechanism of Action:

Jakura 5 mg contains tofacitinib as an active substance that works by inhibiting janus kinase (JAK) enzymes, specifically JAK1 and JAK3 which are pertinent to the signaling pathways of multiple inflammatory cytokines. Jakura 5 mg works by blocking the enzymes that cause inflammation, reducing inflammation and relieving symptoms.

Dosage & Administration

Indication-based Dosage: For various conditions, Jakura 5 mg dosage would differ between individuals based on clinical judgement. You must follow your doctor instructions and keep prescribed dosage. Jakura 5 mg is usually taken orally in tablet form, two times a day.

Side Effects

Common side effects

• Headache
• Nausea
• Diarrhea
• Upper respiratory tract infections

Serious side effects

• Serious infections
• Blood clots
• Cancer
• Tears in the stomach or intestines

You should get in touch with your doctor right away if you have any serious or worrying side effects.

Use In Specific Populations

Pregnancy

It is a category C drug; it is harmful during pregnancy; it is taken only if the benefits are higher than the risks.

Lactation

It is not known whether Jakura 5 mg passes into breast milk. Discuss with doctor before breastfeeding while using this medication.

Precautions & Warnings

Gastrointestinal Events: Monitor perforations in at-risk populations.

Lab Monitoring: Recurrent blood lymphocytes, neutrophils, hemoglobin, and liver enzyme, lipids.

Vaccines: No live vaccines for the course of treatment.

Hematologic Abnormalities: Not Intended for use and should not be administered to individuals with severely low blood counts.

Renal & Liver Impairment: Adjust for moderate; avoid in severe hepatic impairment.

Cancer Risk: Higher risk of lymphoma and skin cancers.

Pregnancy & Breastfeeding: Only if vital; consult doctor.

Drug Interactions: Reduce dose with CYP3A4/CYP2C19 inhibitors; avoid CYP inducers.

Presentation

Storage Conditions

Store at room temperature (Below 30°) in a tightly closed container away from moisture and heat.

Manufactured by

The medicine is produced by Abyss Pharma Private Limited, Delhi, India.

For More Related Medicine

Disclaimer: This information is provided solely for educational reasons and should not be considered medical advice. Always consult with your doctor or healthcare professional before taking any drug.